An August 17 commentary in the New England Journal of Medicine (here) by FDA
Commissioner Scott Gottlieb and Center for Tobacco Products Director Mitchell
Zeller raises some concern about the agency’s new tobacco regulation strategy.
The piece touches on “less harmful tobacco products,” which Commissioner
Gottlieb wrote favorably about earlier (here),
but it includes descriptors – “potential” (four times) and “conceivable” (once)
– that suggest the authors are not convinced that e-cigarettes are truly lower-risk.
Smokeless tobacco, already demonstrated to be vastly safer than cigarettes, isn’t
mentioned.
In their commentary, the FDA officials advocate for radical nicotine
reduction (RNR) in cigarettes.
RNR is a variation on a failed concept: supply-side
elimination of popular products. Full-on
cigarette prohibition was adopted, then jettisoned, in 12 states from 1899 to
1909 (here). During
Prohibition a decade later, brewers tried to market an alcohol-free product
called near beer (here). That bombed just as badly as Vector Group’s
RNR cigarettes in 2003 (here). Any new RNR products will likely be rejected
as well, causing smokers to seek out higher-nicotine-level products, licit or
otherwise.
Despite a significant expenditure of taxpayer dollars on RNR
research, this approach has not been demonstrated to reduce adult smoking. For
example, a $29 million clinical trial by Dr. Neal Benowitz, reported in 2015, produced
dismal results (my review here).
The FDA commissioner and his co-author remain optimistic: “A
recent 6-week study by Donny et al. showed that cigarettes with lower nicotine
content reduced nicotine exposure and dependence, as well as the number of
cigarettes smoked, as compared with cigarettes with standard nicotine levels.” They are referring to another 2015 report (here), but
that study’s results were unimpressive as well.
Dr. Eric Donny recruited 840 smokers uninterested in
quitting, and randomly provided them with one of seven types of cigarettes to
use for 6 weeks: their usual brand, a full-nicotine study cigarette and five
others with varying low nicotine levels (2% to 33% of the full-nicotine
cigarette). Subjects were paid up to
$835 for 10 clinic visits, which probably contributed to a 92% completion rate.
While it was not surprising that smokers using reduced
nicotine cigarettes had lower nicotine levels in their urine, most of the
low-nicotine smokers (73-81%) admitted that they smoked three or four “wildcat”
cigarettes (products not distributed as part of the study) on 24-35% of days in
the trial.
There was little consistency regarding changes in
dependence. On the Wisconsin scale,
smokers in all groups had lower scores after six weeks than at baseline, with
only one of the reduced nicotine groups significantly lower than the
full-nicotine group. On the Fagerström
scale, three low-nicotine groups were significantly lower than the full-nicotine
group, but the changes from baseline were not impressive. In other words, it is not clear if the
low-nicotine cigarettes reduced dependence.
The number of cigarettes smoked in the Donny study is
interesting. At baseline, every group
was smoking about 15 cigarettes per day.
Although Commissioner Gottlieb and Mr. Zeller imply that low-nicotine
groups smoked fewer cigarettes at the end of the study, they actually averaged
15-16 cigarettes per day. Smokers of
usual-brand and full-nicotine cigarettes smoked 21-22 per day after six weeks, an
increase of 6-7. Perhaps Donny
contributed to this increased consumption by providing full nicotine cigarettes
for free.
Like the Benowitz study, the Donny study does not prove that
reduced-nicotine cigarettes produce meaningful benefits for smokers.
It should be noted that the Donny study was supported by $93.3
million in grants from the National Institute on Drug Abuse and the FDA.
